Ryan Craig, MD, PhD
Assistant Professor

Education & Affiliations
Biography
Dr. Ryan Craig, originally from Baton Rouge, Louisiana, graduated from the Louisiana State University Health Sciences Center New Orleans School of Medicine. Dr. Craig completed his pathology residency and hematopathology fellowship training at the University of Utah in Salt Lake City. He currently serves as the program director for the pathology residency program at the Tulane University School of Medicine.
Dr. Craig chose to teach at Tulane because he wanted to be in New Orleans, closer to family, and was drawn to Tulane’s hematopathology program. He believes New Orleans is the greatest city in the world, offering numerous fun activities throughout the year. His favorite restaurant in New Orleans is Coquette, although he finds it difficult to choose just one. In his personal time, Dr. Craig enjoys traveling, photography, and participating in most sports.
Board Certification
2018: Anatomic and Clinical Pathology, American Board of Pathology
2019: Hematopathology, American Board of Pathology
Appointments & Positions
2020-present: Module Co-Director for Phase I Fundamentals of Human Biology, Tulane University School of Medicine
2020-present: Module Co-Director for Phase II Mechanisms of Disease, Tulane University School of Medicine
2020-present: Pathology Clerkship Director/Pathology Career Advisor for Medical Students, Tulane University School of Medicine
2019-present: Assistant Program Director for AP/CP Pathology Residency, Tulane University School of Medicine
2019-present: Assistant Medical Director of Clinical Chemistry, Tulane University School of Medicine
2019-present: Assistant Professor of Pathology, Tulane University School of Medicine, Tulane University School of Medicine
Publications
Pincus, S.; Craig, R.; Weachter, L.; LaBranche, C.; Nabi, R.; Watt, C.; Raymond, M.; Peters, T.; Song, K.; Maresh, G.; Montefiori, D.; Kozlowski, P. Bispecific Anti-HIV Immunoadhesins That Bind gp120 and gp41 Have Broad and Potent HIV-Neutralizing Activity. Vaccines 2021, 9(7), 774.
Ibrahim M, Chen R, Vegel A, Panse K, Bhyravabhotla K, Harris K, Craig R, Safah H, Saba NS, Socola F. 2021. Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen. Leuk Res. 2021 April 22;106:106583
Craig RB, Summa CM, Corti M, Pincus SH. 2012. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One, 2012;7(10):e46778
Craig R, Cutrera J, Zhu S, Xia X, Lee YH, Li S. 2008. Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing gene product within on into tumors. Molecular Therapy, 2008 May;16(5):901-6.
Craig R, Li S. 2006. Function and molecular mechanisms of tumor-targeted peptides for delivering therapeutic genes and chemical drugs. Mini Reviews in Medicinal Chemistry, 2006 Jul;6(7):757-64.